Drug Trial News

RSS

Once-weekly oral tablet proves highly effective for HIV care

An international clinical trial led by researchers including Professor Chloe Orkin of Queen Mary University of London has shown that a once-weekly oral treatment for HIV is as effective as one of today's leading daily therapies, offering the potential for a new treatment option that could reduce the burden of lifelong daily pill-taking.

29 Jul 2026

Deramiocel cell therapy slows muscle and heart damage in advanced DMD

A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD), and may also slow heart damage in those who already have heart muscle disease, a phase 3 clinical trial published in The Lancet has found.

29 Jul 2026

Oral semaglutide reduces heavy drinking in adults with alcohol use disorder

A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy drinking in adults with Alcohol Use Disorder (AUD).

29 Jul 2026

THC and CBD combination rapidly reduces advanced dementia agitation

A combination of CBD and THC rapidly and significantly reduces agitation in hospice-eligible people with dementia, suggest topline results from the Phase 2 LiBBY (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol) clinical trial.

28 Jul 2026

Remdesivir protects kidney and heart health in transplant recipients

Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of COVID-19 diagnosis and who received at least three consecutive days of therapy were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascular or kidney problems up to a year later, according to findings from a target trial emulation study that published in JAMA Network Open.

28 Jul 2026

Major clinical trial aims to transform the prevention of recurrent urinary tract infections

European-funded consortium brings together researchers from 13 countries to evaluate bacteriophage therapy as a potential alternative to antibiotics for recurrent urinary tract infections.

28 Jul 2026

Casdatifan demonstrates durable responses in advanced kidney cancer trial

A new multi-center clinical study is shedding light on a potential new approach for patients with advanced kidney cancer, offering measurable clinical responses alongside a clearer view into how the disease operates beneath the surface.

27 Jul 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Oral antibiotics safely shorten hospital stays for children with pneumonia

Children hospitalized with severe pneumonia can safely switch from injectable to oral antibiotics once they begin to recover, allowing many to return home sooner and complete treatment outside hospital.

23 Jul 2026

Oral drug avatrombopag reduces chemotherapy treatment delays, trial finds

In a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo.

20 Jul 2026

Experimental drug shows promise against NRAS-driven melanoma

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

16 Jul 2026

Long-term lenalidomide maintenance shows no survival advantage in multiple myeloma

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment.

16 Jul 2026

Extended myeloma maintenance therapy shows no additional survival benefit

A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide beyond two years after initial treatment for standard-risk multiple myeloma did not improve overall survival compared with stopping treatment after two years.

15 Jul 2026

Breakthrough to give over 40,000 blind and low vision children access to coding

...

15 Jul 2026

Medical THC and CBD formulation significantly reduces late-life dementia agitation

In a first-of-its-kind clinical trial, U.S. researchers have found that people with agitation and dementia in late life who took a special medical formulation of two active ingredients found in marijuana – THC and CBD – had significantly less agitation compared to people who received a placebo.

14 Jul 2026

Bifidobacterium-based oral vaccine enhances anti-tumor immunity in clinical study

A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity.

14 Jul 2026

Study reports a counterintuitive new approach to treating mesothelioma

Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year.

14 Jul 2026